Recently, it was found that osimertinib could effectively treat LUAD with T790M mutation after resistance to first- or second-generation EGFR-TKIs3,12, however, osimertinib treatment could also endow the tumor with resistance to this drug and this resistance mechanism remains unknown. This evidence concerns the gene EGFR and neoplasm.